Companies › Krystal Biotech
7 active drug programs in 8 registered trials: 7 Phase 1, 1 Phase 3; Other, Oncology, Metabolic and endocrine, Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KB803 Replication-defective, non-integrating HSV-1 expressing human collagen VII protein | COL7A1 | Phase 3 | Dystrophic Epidermolysis Bullosa | Dec 2026 |
| KB407 Replication-defective HSV-1 expressing full-length human CFTR | CFTR | Phase 1 | Cystic Fibrosis | Dec 2026 |
| KB408 Replication-defective HSV-1 vector expressing full-length human SERPINA1 | SERPINA1 | Phase 1 | Alpha 1-Antitrypsin Deficiency | Dec 2026 |
| KB801 Replication-defective, non-integrating HSV-1 vector delivering human nerve growth factor ( | NGF | Phase 1 | Neurotrophic Keratitis | Dec 2026 |
| KB707 Genetically modified oncolytic herpes simplex virus type 1 (oHSV-1) | – | Phase 1 | Lung Cancer, Non-small Cell; Cancer | Feb 2027 |
| KB301 Replication-incompetent, non-integrating HSV-1 vector expressing human type III collagen | COL3 | Phase 1 | Skin Roughness | May 2029 |
| KB304 HSV-1 vector delivering human collagen (COL3) and elastin (tropoelastin) genes | COL3, ELN | Phase 1 | Wrinkles in Decolletage | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06724900 | KB304 | Phase 1 | Wrinkles in Decolletage | Other | Jul 2025 |
| NCT06049082 | KB408 | Phase 1 | Alpha 1-Antitrypsin Deficiency | Metabolic and endocrine | Dec 2026 |
| NCT07016750 | KB803 | Phase 3 | Dystrophic Epidermolysis Bullosa | Other | Dec 2026 |
| NCT06999733 | KB801 | Phase 1 | Neurotrophic Keratitis | Ophthalmology | Dec 2026 |
| NCT05504837 | KB407 | Phase 1 | Cystic Fibrosis | Respiratory | Dec 2026 |
| NCT06228326 | KB707 | Phase 1 | Lung Cancer, Non-small Cell | Oncology | Feb 2027 |
| NCT05970497 | KB707 | Phase 1 | Cancer | Oncology | Jul 2027 |
| NCT04540900 | KB301 | Phase 1 | Skin Roughness | Other | May 2029 |
Cash and short-term investments of $912m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Daewoong Pharmaceutical Axogen Ascendis Pharma argenx Novadip Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.